JMP Securities Reiterates Market Outperform on Structure Therapeutics, Maintains $91 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Structure Therapeutics (NASDAQ:GPCR), maintaining a $91 price target.
March 08, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reaffirms a Market Outperform rating on Structure Therapeutics, with a $91 price target.
The reiteration of a Market Outperform rating and a high price target of $91 by JMP Securities for Structure Therapeutics suggests a strong bullish outlook on the stock. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100